Table 2.
Change from baseline to the last hour of the study (240–300 min) in plasma glucose concentration and EGP in study 1, study 2 (glucose clamp), and study 3 (pancreatic clamp)
| Dapagliflozin | Placebo | Difference (%) | P value | |
|---|---|---|---|---|
| Plasma glucose, mg/dL (%) | ||||
| Study 1: EGP | −29 ± 4 (−20.4) | −17 ± 3 (−12.6) | −12 (−7.8) | 0.03 |
| Study 2: EGP + glucose clamp | +3 ± 1 (+2.2) | 1 ± 1 (1) | +2 (+1.6) | NS |
| Study 3: EGP + pancreatic clamp | −30 ± 4 (−19.4) | −7 ± 5 (−3.1) | −23 (−16.3) | 0.0008 |
| EGP, mg/kg/min (%) | ||||
| Study 1: EGP | +0.10 ± 0.1 (+2.7) | −0.56 ± 0.11 (−19.6) | +0.66 (+22.3) | <0.0001 |
| Study 2: EGP + glucose clamp | −0.57 ± 0.12 (−26.1) | −1.28 ± 0.172 (−46.6) | +0.71 (+20.5) | 0.01 |
| Study 3: EGP + pancreatic clamp | −0.23 ± 0.09 (−7.9) | −0.48 ± 0.05 (−18.5) | +0.25 (+10.6) | 0.04 |
Values are mean ± SEM (%). The P value represents the difference between the change in plasma glucose concentration and the change in EGP between the dapagliflozin-treated and placebo-treated groups.